The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

Before 2009, nonsmall cell lung cancer (NSCLC) was one disease entity treated by cytotoxic
chemotherapy that provided a response rate of 20–35% and a median survival time (MST) of …

Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most
frequent “actionable” alterations in non–small cell lung cancer (NSCLC). Typified by high …

Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …

The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …

The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …